Category: Company News
On Wednesday, August 1st, Merit Medical is hosting a first ever on-campus job fair at its South Jordan, Utah, headquarters. Openings for careers in production, molding, warehouse, and assembly are available. Continuous growth and a strong demand for products have prompted local talent recruitment. Founded in 1987, Merit Medical started with a single device idea […]
Merit Medical prides itself on proactively meeting customer needs and delivering a diverse range of high-quality products. From diagnostic and interventional wires to catheters and microcatheters, our innovative product lines are designed with you in mind, offering many advantages over competing devices. Take a look at some of our most trusted products and discover how […]
At Merit Medical, our commitment to improving the lives of healthcare professionals and their patients goes beyond the manufacturing process. More than just a medical device company, we provide services that ensure our customers get the most out of our products. An excellent example of this service is our newly launched MyAspira.com, a mobile-optimized online […]
Merit Medical prioritizes the health and wellness of our employees. Out of the many benefits we offer, the on-site Merit Care Clinic located at our South Jordon, Utah, headquarters epitomizes this attitude. “There is so much benefit for having the clinic here,” says Nicole Priest, MD, medical director and practitioner at the Merit Care Clinic. […]
We’re excited to be exhibiting at this year’s Vascular Access for Hemodialysis Symposium – VASA 2018. The symposium will be held May 10-12 in New Orleans and is considered to be a premier educational event by professionals involved in the management of vascular access. Merit will be hosting an educational symposium as well as showcasing […]
Thirty years ago, Merit Medical got its start by doing one simple thing: paying close attention to the clinical needs of physicians. At a time when glass syringes were the industry standard, Merit wanted to create something better. From this vision, the polycarbonate Coronary Control Syringe was born. It was the first of its kind and it was Merit’s first manufactured medical device on the market.
We sat down with Fred Lampropoulos, Chairman, CEO, and Founder of Merit Medical, to hear the full story of how this single innovation led to the rise of an international corporation that now employs almost 5,000 individuals and generates $750 million in global revenues.
“At the time, I had left as Chairman and CEO of Utah Medical, voluntarily. I really wanted to look at my life. I had thought about going to medical school,” Lampropoulos says. “After that, I decided I was going to start up a new company.”
In order to understand the clinical needs of the cardiology world, Fred did what any eager anthropologist would do and went native. He began spending much of his time with thoracic surgeons and cardiologists, scrubbing in on cases and observing everything possible. He describes this point in his life as a time he learned most simply by watching. Doing so allowed him to anticipate the needs of physicians and flex his creative muscles.
In one memorable instance, he describes a time when he noticed clinicians taking a spike, taping it onto a bottle of contrast media with the spike not fully inserted. “I could never figure out why they were doing that,” Lampropoulos recalls. “I asked somebody and he said, ‘The stuff in this bottle is really expensive. We want to be able to have the spike where it’s at the lowest point possible. [The spike] either falls out, or someone will just barely tap it, and it’ll fall out. And you’ve got contrast [all over], which is very messy. So, we tape it.’”
This led to Fred’s first prototype.
“I came up with an idea that we’d develop a spike that had a little [part] you could push and the teeth would come over the head of the bottle and it would hold in there. It wouldn’t fall out,” Lampropoulos explains. “It was just observing and listening.”
As time went on, the art of observing and listening—that was once the foundation of a burgeoning business plan—turned into millions of dollars in sales and what sets Merit apart in the medical device industry today.
Referring to another unforgettable case, Fred describes a time when he observed a physician using a syringe filled with contrast and blood. “He was expelling it into a metal basin and [its contents] came up over the top and rolled down on the drape. It went all over the place,” Lampropoulos describes. “I went to the plant in the morning, got a couple of engineers together and said, “This is what I observed. This is what I heard. This is what I want to do.”
In a matter of hours, Fred’s team came back with a prototype, now sold as the Merit BackStop® Disposal Systems. “It was literally from just being there,” Lampropoulos says. “I think we have sold, over the years, 100 million dollars worth of those BackStops. But more important than just selling something is the fact that we have a containment device that helps to minimize bloodborne and airborne pathogens. That was the key. You can watch and listen, but it has to meet a customer need at the same time.”
As a US military officer and combat officer, Fred learned the importance of observing and listening, while simultaneously making decisions quickly. “You take a look at the business, how you strengthen it, and how you gain an advantage over your competitors,” Lampropoulos explains. “There are a lot of pieces that go into that.”
One significant piece that Fred attributes much of his success to is that of teamwork. An avid baseball fan, he compares the well-oiled machine that is Merit Medical to a “team that can play all the positions and can deliver runs and hits.” Full of “very competent, hardworking people who share a vision,” Merit Medical has been able to expand internationally.
With facilities in the US, The Netherlands, France, Ireland, China, Mexico, Brazil, Canada, Singapore, and Australia, Fred says Merit encompasses a core philosophy no matter where they are. “We’ve been able to build a company that really has encompassed a strategy. Whether you’re in Singapore, Galway, Tijuana, or Toronto, there’s a core of beliefs, standards, and efforts on how we all fit into this puzzle that ends up very candidly looking like a masterpiece.”
One only has to read Merit’s vision to see that it’s a customer-focused company in healthcare. Determined each day to make a difference by “delivering products that improve the lives of people, families, and communities throughout the world,” Merit prides itself on driving the cost of medicine down. “I remember our inflation devices when we first started were selling for $85,” Lampropoulos continues. “Today, they sell for $30. We’ve made tools that make it easier for a physician to treat a patient. That’s a big deal.”
By providing tools that simplify and improve patient care, Merit has been able to make several primary therapies more accessible. Peritoneal dialysis, catheter ablation, uterine fibroid embolization (UFE), and the recent FDA-approved prostatic artery embolization (PAE) are only a handful of therapies Merit supplies with state-of-the-art tools and devices. “There are a lot of things we’re doing for patients, and in some cases, they wouldn’t have an alternative,” Lampropoulos notes. “We treat and save 15,000 lives a day. That number keeps going up.”
Looking into the future, Fred believes that in order to continue this crucial work, Merit must remain a steadfast leader in emerging therapies and technologies. Uninterested in short-term business deals, Fred says Merit will maintain its vision and invest long-term. “It’s a huge advantage over others who are being consolidated or are flipping a company or just trying to be a serial entrepreneur. It’s just never what I wanted to do,” Lampropoulos clarifies. “I wanted to build something of lasting value and I think we’ve done that.”
Long-term vision is what Fred says has done more than just make money. Because of the family values Fred has infused in his company, Merit has created countless jobs, fed and educated families, and helped send their children to college. “In some cases, we’re hiring their kids now as our engineers,” Lampropoulos adds. “That is very gratifying.”
From a community standpoint, Merit has supported the arts and sciences, as well as worked with homeless and youth centers—places where Fred believes Merit has a corporate responsibility. “It’s not some newfound belief. It’s something that we started out from the very beginning. I think we have been and have tried to be, within our means, a responsible corporate leader.”
When asked if he’s proud of all he has accomplished in the last 30 years, Fred remains humble. “I don’t think much about what I’ve done because I don’t have much time to do that,” he responds. “I don’t want to look at the back window, I want to look out the front window. Did we think we would be here today? The answer is we hoped we would be.”
An important part of Merit Medical’s business involves working with Group Purchasing Organizations and Integrated Delivery Networks around the United States. April Sanchez, Merit’s Supervisor of Strategic Accounts Contract Management, speaks about her team’s role to provide important financial impact and analysis of Merit’s contracts with these GPOs and IDNs. The efforts of Strategic Accounts allows Merit to form lasting relationships with customers and provides them with access to products to improve and save the lives of their patients.
February 21st 2017 / 3pm MT
SOUTH JORDAN, Utah, July 06, 2016 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology, radiology and endoscopy, today announced that it has acquired DFINE, Inc. headquartered in San Jose, California, in a merger transaction through which DFINE has become a wholly-owned subsidiary of Merit.
The purchase consideration was approximately $97.5 million in cash and was financed by a group of banks led by Wells Fargo and included Bank of America, HSBC and U.S. Bank.
DFINE produced revenues of $33.4 million in 2015, with approximately 75% of revenues generated in the United States and 25% outside the United States. DFINE’s products are directed to vertebral augmentation (kyphoplasty and vertebralplasty), as well as targeted radiofrequency ablation of metastatic spinal tumors. DFINE’s product lines have 510(k) clearance and CE marking.
“We are delighted to have DFINE join Merit,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer. “Our relationship began a few years ago when Merit was asked to provide key device components for DFINE’s StabiliT® and StabiliT MX® products. In addition to the spinal compression fracture segment, we believe DFINE’s Star™ Tumor Ablation Kit complements and enhances Merit’s oncology business.”
“We plan to combine Merit’s oncology segments, including embolics, microcatheters and biopsy products into a newly created interventional oncology and spine division (IOS),” Lampropoulos said. “We believe the restructuring of the sales divisions – cardiovascular, peripheral and IOS – will enable us to devote greater focus on Merit’s broad portfolio of products, align our sales and marketing efforts with Merit’s goal of achieving a more therapeutic and disease state centered product offering, and enhance opportunities for future growth.”
“We believe the opportunity for growth with these best-in-class products is substantial in the United States and also in international markets where Merit already has a broad footprint,” Lampropoulos continued. “Although DFINE has a presence in Germany and Austria, as well as limited distribution partners, we believe there are many opportunities in Australia, Canada, Japan, China, the Nordic countries and other regions. We anticipate that DFINE’s IP portfolio of approximately 110 U.S. and international patents will provide substantial coverage for many years ahead.”
The effect of the DFINE acquisition on Merit’s non-GAAP earnings for the balance of 2016 is expected to be neutral due to business restructuring and consolidation expenses and is expected to be dilutive on a GAAP basis by $0.24-$0.26 per share due to intangible amortization and one-time reorganization costs. In 2017, Merit anticipates the effect of the acquisition on Merit’s non-GAAP earnings to be $0.05-$0.08 per share and to be dilutive on a GAAP basis by $0.05-$0.07 per share. Merit believes the acquisition will increase its gross margin by approximately 80 basis points on a non-GAAP basis and 55 basis points on a GAAP basis.
Canaccord Genuity acted as Merit’s financial advisor for this transaction. Piper Jaffray acted as DFINE’s financial advisor.
CONFERENCE CALL TODAY Merit invites all interested parties to participate in its conference call discussing the acquisition (conference ID 41983902) today, Wednesday, July 6, 2016, at 11:00 a.m. Eastern (10:00 a.m. Central, 9:00 a.m. Mountain, and 8:00 a.m. Pacific). The domestic telephone number is (844) 578-9672, and the international number is (508) 637-5656. A live webcast of the call and a slide deck showcasing the products and details of the DFINE acquisition are available at www.merit.com.
ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy. Merit serves hospitals, acute care facilities and clinics worldwide, with a domestic and international sales force totaling approximately 200 individuals. Merit employs approximately 4,000 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; and Mannheim, Germany.
Statements contained in this release which are not purely historical, including, without limitation, statements regarding anticipated revenues, earnings or other financial items; Merit’s plans and objectives for future operations; proposed products or services; integration, development or commercialization of the DFINE operations and assumptions underlying any of the foregoing , are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit’s Annual Report on Form 10-K for the year ended December 31, 2015. Such risks and uncertainties include risks relating to Merit’s acquisition of DFINE; Merit’s efforts to integrate, manage and develop DFINE’s operations and products; expenses associated with the integration, management and development of those operations and products; product recalls and product liability claims; expenditures relating to research, development, testing and regulatory approval of Merit’s products (including the DFINE products) and risks that such products may not be developed successfully or approved for commercial use; regulation of the medical device industry; Merit’s need to generate sufficient cash flow to fund its debt obligations, capital expenditures, and ongoing operations; restrictions on Merit’s liquidity or Merit’s ability to operate its business in compliance with its debt agreements; possible infringement of its technology (including the DFINE technology) or the assertion that such technology infringes the rights of other parties; changes in the prices or supply of commodity components; changes in economic and industry conditions in the United States and other countries; termination or interruption of relationships with suppliers, or failure of suppliers to perform; fluctuations in exchange rates; development of new products and technology that could render Merit’ products (including the DFINE products) obsolete; changes in key personnel; potential healthcare regulatory and policy changes; and other factors referred to in Merit’s Annual Report on Form 10-K for the year ended December 31, 2015 and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.
Contact: Anne-Marie Wright, Vice President, Corporate Communications Phone: (801) 208-4167 e-mail: [email protected] Fax: (801) 253-1688